Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.

Details

Serval ID
serval:BIB_B675D0338C57
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
Journal
Leukemia
Author(s)
Moreau P., Attal M., Garban F., Hulin C., Facon T., Marit G., Michallet M., Doyen C., Leyvraz S., Mohty M., Wetterwald M., Mathiot C., Caillot D., Berthou C., Benboubker L., Garderet L., Chaleteix C., Traullé C., Fuzibet J.G., Jaubert J., Lamy T., Casassus P., Dib M., Kolb B., Dorvaux V., Grosbois B., Yakoub-Agha I., Harousseau J.L., Avet-Loiseau H., and 
ISSN
0887-6924
Publication state
Published
Issued date
2007
Peer-reviewed
Oui
Volume
21
Number
9
Pages
2020-2024
Language
english
Abstract
One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed. The median overall survival (OS) and event-free survival (EFS) were 41.4 and 21 months, respectively, as compared to 65 and 37 for patients included in the IFM99 trials without t(4;14) (P<10(-7)). We identified a subgroup of patients presenting at diagnosis with both low beta(2)-microglobulin <4 mg/l and high hemoglobin (Hb) >/=10 g/l (46% of the cases) with a median OS of 54.6 months and a median EFS of 26 months, respectively, which benefits from high-dose therapy (HDT); conversely patients with one or both adverse prognostic factor (high beta(2)-microglobulin and/or low Hb) had a poor outcome. The achievement of either complete response or very good partial response after HDT was also a powerful independent prognostic factor for both OS and EFS.
Keywords
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 4, Cytarabine, Dexamethasone, Disease-Free Survival, Female, Follow-Up Studies, Genetic Heterogeneity, Hemoglobins, Humans, Male, Middle Aged, Multiple Myeloma, Multivariate Analysis, Prognosis, Retrospective Studies, Translocation, Genetic, Vincristine, beta 2-Microglobulin
Pubmed
Web of science
Open Access
Yes
Create date
28/01/2008 8:32
Last modification date
20/08/2019 15:24
Usage data